Page 24 - CBAC Newsletter 2016

Reference List (Continued)

93. Borsotto M, Cavarec L, Bouillot M, Romey G, Macciardi F, Delaye A, Nasroune M, Bastucci M, Sambucy JL,
Luan JJ, Charpagne A, Jouet V, Leger R, Lazdunski M, Cohen D, Chumakov I. PP2A-Bgamma subunit and
KCNQ2 K+ channels in bipolar disorder. Pharmacogenomics J. 7, 123-132. 2007.

94. Gilling M, Rasmussen HB, Calloe K, Sequeira AF, Baretto M, Oliveira G, Almeida J, Lauritsen MB, Ullmann R,
Boonen SE, Brondum-Nielsen K, Kalscheuer VM, Tumer Z, Vicente AM, Schmitt N, Tommerup N.
Dysfunction of the Heteromeric KV7.3/KV7.5 Potassium Channel is Associated with Autism Spectrum
Disorders. Front Genet. 4, 54, 2013.

95. Li S, Choi V, Tzounopoulos T. Pathogenic plasticity of Kv7.2/3 channel activity is essential for the induction of
tinnitus. Proc Natl Acad Sci. USA. 110, 9980-9985, 2013.

96. Singh NA, Westenskow P, Charlier C, Pappas C, Leslie J, Dillon J, Anderson VE, Sanguinetti MC, Leppert MF,
BFNC Physician Consortium. KCNQ2 and KCNQ3 potassium channel genes in benign familial neonatal
convulsions: expansion of the functional and mutation spectrum. Brain. 126, 2726-2737, 2003.

97. Constanti A, Brown DA. M-Currents in voltage-clamped mammalian sympathetic neurones. Neurosci Lett.
24, 289-294, 1981.

98. Miceli F, Soldovieri MV, Martire M, Taglialatela M. Molecular pharmacology and therapeutic potential of
neuronal Kv7-modulating drugs. Curr Opin Pharmacol. 8, 65-74, 2008.

99. Gunthorpe MJ, Large CH, Sankar R. The mechanism of action of retigabine (ezogabine), a first-in-class
K+ channel opener for the treatment of epilepsy. Epilepsia. 53, 412-424, 2012.

100. Tatulian L, Delmas P, Abogadie FC, Brown DA. Activation of expressed KCNQ potassium currents and native
neuronal M-type potassium currents by the anti-convulsant drug retigabine. J. Neurosci. 21,
5535-5545, 2001.

101. Wuttke TV, Seebohm G, Bail S, Maljevic S, Lerche H. The new anticonvulsant retigabine favors
voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate.
Mol Pharmacol. 67, 1009-1017, 2005.

102. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic
drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res. 61, 1-48, 2004.

103. Njung'e K, Handley SL. Evaluation of marble-burying behavior as a model of anxiety.
Pharmacol Biochem Behav. 38, 63-67, 1991.

104. Shepherd JK, Grewal SS, Fletcher A, Bill DJ, Dourish CT. Behavioural and pharmacological characterisation of
the elevated "zero-maze" as an animal model of anxiety. Psychopharmacology. 116, 56-64, 1994.

105. Blackburn-Munro G, Jensen BS. The anticonvulsant retigabine attenuates nociceptive behaviours in rat
models of persistent and neuropathic pain. Eur J Pharmacol. 460, 109-116, 2003.

106. Dost R, Rostock A, Rundfeldt C. The anti-hyperalgesic activity of retigabine is mediated by KCNQ potassium
channel activation. Naunyn Schmiedebergs Arch Pharmacol. 369, 382-390, 2004.

107. Nielsen AN, Mathiesen C, Blackburn-Munro G. Pharmacological characterisation of acid-induced muscle
allodynia in rats. Eur J Pharmacol. 487, 93-103, 2004.

108. Rostock A, Tober C, Rundfeldt C, Bartsch R, Engel J, Polymeropoulos EE, Kutscher B, Loscher W, Honack D,
White HS, Wolf HH. D-23129: a new anticonvulsant with a broad spectrum activity in animal models of
epileptic seizures. Epilepsy Res. 23, 211-223, 1996.

109. Nicolson A, Leach JP. Future prospects for the drug treatment of epilepsy. CNS Drugs. 15, 955-968, 2001.
110. Tober C, Rostock A, Rundfeldt C, Bartsch R. D-23129: a potent anticonvulsant in the amygdala kindling

model of complex partial seizures. Eur J Pharmacol. 303, 163-169, 1996.
111. Rundfeldt C, Netzer R. Investigations into the mechanism of action of the new anticonvulsant retigabine.

Interaction with GABAergic and glutamatergic neurotransmission and with voltage gated ion channels.
Arzneimittelforschung. 50, 1063-1070, 2000.

20 | CBAC Center Heartbeat